Additional Volume Molnupiravir (EIDD-2801/MK-4482) Supply Agreement for Pandemic Purposes
key details
| Status | complete |
|---|---|
| Category (CPV) | 33600000 |
| Procedure | limited |
| OCID | ocds-h6vhtk-030bfd |
Award
| Supplier | Value | Date | Status |
|---|---|---|---|
| Merck Sharpe and Dohme (UK) Limited | · | · | active |
description
Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative. <br/>This agreement is for the procurement of 1,750,000 units of Molnupiravir (EIDD-2801/MK-4482). It is one of the first oral and direct-acting antiviral drugs globally and the first to receive regulatory approval and is part of the UK’s multi-layered approach to COVID-19.
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 17 Jan 2022 | Contract award notice (F03) | Earlier regulations | 001380-2022 |
more from Department of Health and Social Care
- DHSC: Fin: Interim Senior Financial Accountant · £94,250 · 29 Jul 2026
- DHSC: Fin: Interim Financial Accountant · £66,400 · 29 Jul 2026
- DHSC Sinogo claim legal support · £100,000 · 22 Jul 2026
- National Institute for Health and Care Research (NIHR) pre-action letter advice · £80,000 · 22 Jul 2026
- DHSC: ASC: Waves 3 – 5 of the Adult Social Care Workforce Employee Survey · 15 Jul 2026
- Hugh's Report - MH Impact of Life-Threatening Child Illness on Families 2026 · 26 Jun 2026
- Library Mgmt and Enquiry System, E-Archive · £22,578 · 22 Jun 2026
- DHSC: Leeds Maternity Review legal services · £432,000 · 22 Jun 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.